.jpg?width=1184&height=426&name=ASC-Blog_Thumb-2026-01a-DCATweek%20(1).jpg)
Ascendia Pharmaceutical Solutions will participate in DCAT Week 2026, the annual global forum focused on business development across the pharmaceutical manufacturing and supply chain ecosystem. DCAT Week convenes decision-makers from pharmaceutical companies, biotechnology organizations, and contract service providers to advance outsourcing strategies, licensing discussions, and long-term partnerships. Ascendia Pharmaceutical Solutions’ participation underscores its role as a specialized CDMO supporting complex drug product development and manufacturing programs.
Leadership Availability for Strategic Discussions
Jim Huang, Ph.D., Chief Executive Officer; Bob Bloder, Chief Business Officer; Dr. Shaukat Ali, Senior Director of Scientific Affairs; Jared Hahn, Senior Director of Business Development; and Julie Hilton, Executive Director of Business Development, will represent Ascendia Pharmaceutical Solutions during DCAT Week 2026. The team will host meetings at the InterContinental Barclay Hotel in New York City, providing sponsors with direct access to executive, scientific, and commercial leadership.
Discussions will address development strategy, formulation and bioavailability challenges, clinical supply planning, and commercial manufacturing readiness. Engagement with Ascendia Pharmaceutical Solutions’ leadership team supports focused, technically grounded conversations that align development objectives with scalable manufacturing execution.
Click here to book your meeting with Jim and Bob in advance of DCAT Week!
Integrated CDMO Services Supporting Drug Product Development
Ascendia Pharmaceutical Solutions provides integrated contract development and manufacturing services designed to address technical and operational challenges in drug product development. Capabilities include formulation development, spray drying, particle engineering, bioavailability enhancement, clinical trial material manufacturing, and commercial-scale production. These services support small-molecule programs requiring specialized formulation approaches and scalable manufacturing pathways.
Specialized Expertise in Bioavailability and ParticleEngineering
Ascendia Pharmaceutical Solutions is known for its technical expertise in improving solubility, stability, and bioavailability for poorly soluble compounds. Advanced spray drying and particle engineering technologies areapplied to reduce development risk and support consistent product performance. This focus enables pharmaceutical and biotechnology companies to progress complex candidates through development with greater predictability and regulatory readiness.
Clinical and Commercial Manufacturing Readiness
Ascendia Pharmaceutical Solutions operates GMP-compliant facilities supporting both clinical and commercial drug product manufacturing. Quality systems, process scalability, and regulatory alignment are integrated into development programs to support smooth transitions between development phases. These capabilities are designed to minimize supply chain disruption and supportlong-term commercial success.
Engaging With Ascendia Pharmaceutical Solutions During DCAT Week2026
DCAT Week 2026 provides a structured environment for focused discussions onoutsourcing, development strategy, and manufacturing execution. Ascendia Pharmaceutical Solutions will engage with current and prospective partners to evaluate technical requirements, development timelines, and manufacturing needs. Meetings will emphasize practical solutions to formulation and scale-upchallenges.
Schedulea DCAT Week 2026 Meeting With Ascendia Pharmaceutical Solutions
Companies attending DCAT Week 2026 are encouraged to schedule a meeting with Ascendia Pharmaceutical Solutions to discuss current or upcoming drug development programs. Meetings with executive leadership will take place at the InterContinental Barclay Hotel in New York City. To reserve a meeting time, interested parties should book directly in advance. Direct engagement supports timely, focused discussions on how Ascendia Pharmaceutical Solutions’ CDMO capabilities can support development and commercialization objectives.